• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by LeonaBio Inc.

    4/1/26 4:05:29 PM ET
    $LONA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LONA alert in real time by email
    S-8 1 lona-20260401.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on April 1, 2026

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S‑8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    LeonaBio, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

     

    45-3368487

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

     

     

    18706 North Creek Parkway, Suite 104

    Bothell, WA 98011

    (Address of principal executive offices, including zip code)

     

     

    2026 Equity Incentive Plan

    (Full title of the plan)

     

     

    Mark Litton, Ph.D.

    President and Chief Executive Officer

    LeonaBio, Inc.

    18706 North Creek Parkway, Suite 104

    Bothell, WA 98011

    (425) 620-8501

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Michael Nordtvedt

    Bryan D. King

    Wilson Sonsini Goodrich & Rosati,

    Professional Corporation

    701 Fifth Avenue

    Suite 5100

    Seattle, WA 98104-7036

    (206) 883-2500

    Mark Worthington

    General Counsel, Chief Compliance Officer & Corporate Secretary

    LeonaBio, Inc.

    18706 North Creek Parkway, Suite 104

    Bothell, Washington 98011

    (425) 620-8501

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐

    Accelerated filer ☐

    Non-accelerated filer ☒

    Smaller reporting company ☒

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (the “Registration Statement”) in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S‑8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Securities and Exchange Commission (the “Commission”):

    (1) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 31, 2026 (the “2025 Form 10-K”);

    (2) All other reports filed with the Commission pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of the fiscal year covered by the 2025 Form 10-K; and

    (3) The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-39503) filed with the Commission on September 9, 2020, pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    The validity of the shares of common stock offered hereby will be passed upon for the Registrant by Wilson Sonsini Goodrich & Rosati, Professional Corporation, Seattle, Washington. Investment funds associated with Wilson Sonsini Goodrich & Rosati, Professional Corporation, hold an aggregate of 1,370 shares of the Registrant’s common stock, which represent less than 1% of the Registrant’s outstanding shares of common stock.

     


     

    Item 6. Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law authorizes a corporation’s board of directors to grant, and authorizes a court to award, indemnity to officers, directors and other corporate agents.

    Our certificate of incorporation contains provisions that limit the liability of our directors and certain of our officers for monetary damages to the fullest extent permitted by the Delaware General Corporation Law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following:

    •
    any breach of their duty of loyalty to us or our stockholders;
    •
    any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
    •
    unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or
    •
    any transaction from which they derived an improper personal benefit.

    Similarly, our officers who at the time of an act or omission as to which liability is asserted consented to or are deemed to have consented to certain service of process rules under Delaware law will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as officers, except for liability in connection with:

    •
    any breach of their duty of loyalty to us or our stockholders;
    •
    any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
    •
    any transaction from which they derived an improper personal benefit; or
    •
    any action by or in the right of the corporation.

    Any amendment, repeal or elimination of these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to that amendment, repeal or elimination. If the Delaware General Corporation Law is amended to provide for further limitations on the personal liability of directors or officers of corporations, then the personal liability of our directors and officers will be further limited to the greatest extent permitted by the Delaware General Corporation Law.

    In addition, our bylaws provide that we will indemnify our directors and officers, and may indemnify our employees, agents and any other persons, to the fullest extent permitted by the Delaware General Corporation Law. Our bylaws also provide that we must advance expenses incurred by or on behalf of a director or officer in advance of the final disposition of any action or proceeding, subject to limited exceptions.

    Further, we have entered into indemnification agreements with each of our directors and executive officers that may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements require us to, among other things, indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also generally require us to advance all expenses reasonably and actually incurred by our directors and executive officers in investigating or defending any such action, suit or proceeding. We believe that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers.

     


     

    The limitation of liability and indemnification provisions in our certificate of incorporation, bylaws and indemnification agreements may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder’s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against our directors and officers as required by these indemnification provisions.

    We have obtained insurance policies under which, subject to the limitations of the policies, coverage is provided to our directors and officers against loss arising from claims made by reason of breach of fiduciary duty or other wrongful acts as a director or officer, including claims relating to public securities matters, and to us with respect to payments that may be made by us to our directors and officers pursuant to our indemnification obligations or otherwise as a matter of law.

    Certain of our non-employee directors may, through their relationships with their employers, be insured or indemnified against certain liabilities incurred in their capacity as members of our board of directors.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

     

    Exhibit

    Number

    Exhibit Description

    Form

    Incorporated by
    Reference

    Filing Date

    File No.

    Exhibit

    99.1

    Specimen common stock certificate of the Registrant

    S-3

    333-292826

    4.1

    January 20, 2026

    99.2

    2026 Equity Incentive Plan

    8-K

     

    001-39503

     

    10.1

     

    March 19, 2026

    99.3

    Form of Stock Option Agreement under the 2026 Equity Incentive Plan

    8-K

     

    001-39503

     

    10.2

     

    March 19, 2026

     

     

     

     

     

     

     

    99.4

    Form of Restricted Stock Award Agreement under the 2026 Equity Incentive Plan

    8-K

     

    001-39503

     

    10.3

     

    March 19, 2026

     

     

     

     

     

     

     

    99.5

    Form of RSU Agreement under the 2026 Equity Incentive Plan

    8-K

     

    001-39503

     

    10.4

     

    March 19, 2026

    99.6

    2020 Equity Incentive Plan, as amended

    10-K

     

    001-39503

     

    10.3

     

    March 31, 2026

    5.1

    Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation

    23.1

    Consent of Independent Registered Public Accounting Firm

    23.2

    Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto)

    24.1

    Power of Attorney (contained on signature page hereto)

    107

    Filing Fee Table

     


     

    Item 9. Undertakings.

    (a)
    The undersigned registrant hereby undertakes:
    (1)
    to file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
    (i)
    to include any prospectus required by Section 10(a)(3) of the Securities Act;
    (ii)
    to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
    (iii)
    to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

    (2)
    that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (3)
    to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    (b)
    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (c)
    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bothell, State of Washington, on April 1, 2026.

     

    LEONABIO, INC.

     

     

    By:

     

    /s/ Mark Litton

     

     

    Mark Litton, Ph.D.

     

     

    President and Chief Executive Officer

     

     


     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark Litton and Robert Renninger, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement, including post-effective amendments, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises, as fully for all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or any of them, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Mark Litton

     

    President, Chief Executive Officer and Director
    (Principal Executive Officer)

     

    April 1, 2026

    Mark Litton

     

     

     

     

     

     

     

    /s/ Robert Renninger

     

    Chief Financial Officer
    (Principal Financial and Accounting Officer)

     

     April 1, 2026

    Robert Renninger

     

     

     

     

     

     

     

     

    /s/ Kelly A. Romano

     

    Chair of the Board of Directors

     

    April 1, 2026

    Kelly A. Romano

     

     

     

     

     

     

     

    /s/ Joseph Edelman

     

    Director

     

    April 1, 2026

    Joseph Edelman

     

     

     

     

     

     

     

    /s/ John M. Fluke, Jr.

     

    Director

     

    April 1, 2026

    John M. Fluke, Jr.

     

     

     

     

     

     

     

    /s/ James A. Johnson

     

    Director

     

    April 1, 2026

    James A. Johnson

     

     

     

     

     

     

     

    /s/ Barbara Kosacz

     

    Director

     

    April 1, 2026

    Barbara Kosacz

     

     

     

     

     

     

     

    /s/ Michael Panzara

     

    Director

     

    April 1, 2026

    Michael Panzara

     

     

     

     

     

     

     

    /s/ Grant Pickering

     

    Director

     

    April 1, 2026

    Grant Pickering

     

     

     

     


    Get the next $LONA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LONA

    DatePrice TargetRatingAnalyst
    2/26/2026Overweight
    Cantor Fitzgerald
    2/19/2026$10.00Neutral → Outperform
    Mizuho
    More analyst ratings

    $LONA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Panzara Michael A.

    4 - LeonaBio, Inc. (0001620463) (Issuer)

    4/13/26 4:59:24 PM ET
    $LONA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Church Kevin

    4 - LeonaBio, Inc. (0001620463) (Issuer)

    4/13/26 4:58:15 PM ET
    $LONA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Kosacz Barbara

    4 - LeonaBio, Inc. (0001620463) (Issuer)

    4/13/26 4:56:59 PM ET
    $LONA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LONA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on LeonaBio

    Cantor Fitzgerald initiated coverage of LeonaBio with a rating of Overweight

    2/26/26 8:43:27 AM ET
    $LONA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LeonaBio upgraded by Mizuho with a new price target

    Mizuho upgraded LeonaBio from Neutral to Outperform and set a new price target of $10.00

    2/19/26 7:48:19 AM ET
    $LONA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LONA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer

    Management to be Joined by Two Clinical Leaders in the Breast Cancer Field  Expected to Complete Enrollment in Ongoing ELAINE-3 Phase 3 Registrational Study of Lasofoxifene in Metastatic Breast Cancer in 4Q26 with Data Expected in 2H27 Webinar Event on Wednesday, April 29, 2026, at 12:00 p.m. ET BOTHELL, Wash., April 23, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it will host a virtual Key Opinion Leader event with two leading physician experts in the breast cancer field to discuss the current and evolving treatment la

    4/23/26 4:05:00 PM ET
    $LONA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio's Data

    BOTHELL, Wash., April 21, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, attended the American Association for Cancer Research Annual Meeting 2026 (AACR26), where independent researchers at Virginia Commonwealth University's Massey Comprehensive Cancer Center presented nonclinical data on lasofoxifene, including its potential for a bone protective role in metastatic breast cancer.1 "We are delighted to learn the findings of this independent research at AACR26, attended by an audience of the world's leading oncology researchers. We believe these

    4/21/26 7:00:00 AM ET
    $LONA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update

    Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1-Mutations Received Gross Proceeds of $90 Million in Private Placement Financing of Common Stock and Warrants with Cash-Exercisable Warrants Potentially Providing up to an Additional $146 Million to Support Development of Lasofoxifene Through Key Clinical and Regulatory Milestones Expect to Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Anticipated in 2H 2027

    3/26/26 5:10:00 PM ET
    $LONA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LONA
    SEC Filings

    View All

    SEC Form EFFECT filed by LeonaBio Inc.

    EFFECT - LeonaBio, Inc. (0001620463) (Filer)

    4/2/26 12:15:19 AM ET
    $LONA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by LeonaBio Inc.

    EFFECT - LeonaBio, Inc. (0001620463) (Filer)

    4/2/26 12:15:21 AM ET
    $LONA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by LeonaBio Inc.

    424B3 - LeonaBio, Inc. (0001620463) (Filer)

    4/1/26 9:30:12 PM ET
    $LONA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LONA
    Leadership Updates

    Live Leadership Updates

    View All

    LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer

    BOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Mark F. Kubik as Chief Business Officer. In this role, Mr. Kubik will lead LeonaBio's business development strategy and execution, with responsibility for licensing, partnership strategy, and corporate development initiatives. Mr. Kubik previously served as a strategic consultant to LeonaBio, where he played an instrumental role in the transformational transaction announced in December 2025, in which LeonaBio acquired rights to the Phase 3

    2/3/26 7:00:00 AM ET
    $LONA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care